Oct 19, 2021 8:05am EDT Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
Oct 04, 2021 8:05am EDT Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
Sep 23, 2021 8:05am EDT Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
Sep 07, 2021 8:00am EDT Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
Aug 16, 2021 4:45pm EDT Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Jul 26, 2021 8:42am EDT Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
Jun 18, 2021 6:45pm EDT Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
May 25, 2021 8:00am EDT Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others
May 17, 2021 4:05pm EDT Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity